Frontiers in molecular biosciences

Virus enzymes that help make mRNA vaccines and treatments

Updated

Abstract

Key mechanistic insights on bacteriophage-derived RNA polymerases could enhance mRNA manufacturing efficiency.

  • The efficiency of mRNA manufacturing is crucial for the success of mRNA-based products.
  • Application of the (QbD) framework may improve the critical quality attributes of mRNA drug substances.
  • Critical process parameters and critical material attributes are associated with key performance indicators in mRNA production.
  • The structure-function relationship of T7 RNA polymerase and its engineered mutants could lead to lower immunogenicity in mRNA therapeutics.
  • Alternatives to standard RNA polymerases are discussed in the context of large-scale in vitro transcription processes.

Simplified

Full Text

What this is

  • Bacteriophage-derived RNA polymerases (RNAPs) are crucial for synthesizing mRNA, particularly for vaccines.
  • This review discusses the evolution of RNAPs, focusing on T7 RNAP's role in mRNA manufacturing.
  • It explores the application of the () framework to enhance mRNA production efficiency.
  • The review also examines alternatives to T7 RNAP and the economic implications of improving mRNA manufacturing.

Essence

  • Bacteriophage-derived RNA polymerases, especially T7 RNAP, are central to mRNA synthesis for vaccines. Implementing () principles can optimize production processes, reduce impurities, and enhance economic viability.

Key takeaways

  • T7 RNAP is the gold standard for mRNA synthesis, enabling large-scale production during the COVID-19 pandemic. Its efficiency and specificity make it ideal for industrial applications.
  • () principles can significantly improve mRNA manufacturing by optimizing critical process parameters (CPPs) and critical material attributes (CMAs), leading to better quality attributes (CQAs) of the final product.
  • Exploration of mutant RNAPs and alternatives derived from other bacteriophages may reduce product-related impurities and enhance the efficiency of mRNA synthesis.

Caveats

  • The review primarily focuses on T7 RNAP, which, while extensively characterized, may not fully represent the capabilities of less-studied alternatives. Regulatory hurdles could impede the adoption of these alternatives in industrial settings.
  • Despite the potential benefits of mutant RNAPs, extensive characterization is required to ensure their reliability and effectiveness in large-scale manufacturing.

Definitions

  • Quality by Design (QbD): A systematic approach to pharmaceutical development that emphasizes designing quality into products and processes from the outset.

Simplified

Funding

Competing interests

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free